Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Keysar

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Research : MCR|October 22, 2020
Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse XenograftJ Jason Morton, Nathaniel Alzofon, Stephen B Keysar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesDaniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
JCI Insight|September 21, 2021
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerMehdi Bouhaddou, Rex H Lee, Hua Li, et al.
Molecular Cancer Therapeutics|July 23, 2013
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomasRyan T Anderson, Stephen B Keysar, Daniel W Bowles, et al.
Cancer Research|April 12, 2013
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancerStephen B Keysar, Phuong N Le, Ryan T Anderson, et al.
Journal of the National Cancer Institute|September 17, 2016
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2Stephen B Keysar, Phuong N Le, Bettina Miller, et al.
Oncogene|April 21, 2015
XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancerJ J Morton, G Bird, S B Keysar, et al.
Molecular Oncology|April 24, 2013
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsStephen B Keysar, David P Astling, Ryan T Anderson, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Research : MCR|October 22, 2020
Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse XenograftJ Jason Morton, Nathaniel Alzofon, Stephen B Keysar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesDaniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
JCI Insight|September 21, 2021
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerMehdi Bouhaddou, Rex H Lee, Hua Li, et al.
Molecular Cancer Therapeutics|July 23, 2013
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomasRyan T Anderson, Stephen B Keysar, Daniel W Bowles, et al.
Cancer Research|April 12, 2013
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancerStephen B Keysar, Phuong N Le, Ryan T Anderson, et al.
Journal of the National Cancer Institute|September 17, 2016
Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2Stephen B Keysar, Phuong N Le, Bettina Miller, et al.
Oncogene|April 21, 2015
XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancerJ J Morton, G Bird, S B Keysar, et al.
Molecular Oncology|April 24, 2013
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsStephen B Keysar, David P Astling, Ryan T Anderson, et al.
Pageof 4